Accelerate Your Clinical Trial Enrollment with Foundation Medicine

FOUNDATION MEDICINE®

Leverage timely data and our **extensive testing network** to help you run faster, more efficient trials.

Only **~8% of cancer patients** enroll in **clinical trials**:[1]

1. Clinical trials are hard to recruit.
2. Many patients lack access to clinical trials.

Clinical trials are centralized at academic centers, but many patients are treated at community practices leading to **difficulties in identifying where patients are, at the right time**.

INTRODUCING

FOUNDATIONREACH™

Weekly alerts to you to enable **timely education** for providers about **clinical trials** for their patients.

HOW WE WILL **ACCELERATE YOUR TRIALS**:

Site Identification

Our site planner reports enable clinical trial planning by identifying high-volume sites

Patient Finding

FoundationReach™ weekly alerts help you find eligible patients to recruit

Profiling + Enrollment

Trial Boost™ allows for quick re-analysis of Foundation Medicine clinical results for speedy trial enrollment and reduced patient burden

Foundation Medicine's Clinical Trial Solutions

NOW AVAILABLE FOR ALL PROFILING PARTNERS

FoundationReach™ identifies opportunities for **timely enrollment discussions**.

EXAMPLE: POSITIVE BIOMARKER RESULTS FOR 2022

NTRK1/2/3 *BRCA1/2*

Sample Biopharma HCP outreach informed by FoundationReach™:

> *"We are reaching out about our clinical trial for ovarian cancer patients with BRCA1/2"*
> *...would you be interest in becoming a trial site?"*
> *...would you be interested in referring your patient to the clinical trial?"*

FoundationReach™ program excludes patients tested in California, at Veterans Affairs facilities, and other accounts with contractual restrictions on data sharing, and only applies to genes and biomarkers on current tests that have been reviewed by expert determination.

SITE PLANNER REPORTS

Our site planner reports help **prioritize sites** with **potentially eligible patients**.

UNDERSTAND

Understand the prevalence of your patient cohort to better plan ahead

IDENTIFY

Identify specific sites where patients have been profiled and match molecular eligibility criteria

TRIAL BOOST™

Giving your profiling a **fast pass**.

SPONSORS

Decreased screen fail rates as genomic results are already known

PATIENTS

Reduced burden by avoiding unnecessary biopsies

PROVIDERS

Reduced waiting due to rapid turnaround time (avg <5 days[2])

FOUNDATION MEDICINE COMMERCIAL TEST

Foundation Medicine Clinical Testing

Foundation Medicine IVD Clinical Report

TRIAL BOOST™

Patient consents to clinical trial screening

Foundation Medicine re-processes sequencing data from source report

TRIAL ENROLLMENT

Foundation Medicine delivers IUO or RUO Clinical Trial Assay results

Patient Enrolled

Trial Boost™ leverages global data with the exclusion of Switzerland, China, Japan.

References

1. Joseph M Unger et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. Journal of the National Cancer Institute. 2019; 111(3):245-255.
2. Data on file, Foundation Medicine, Inc, 2023. Time from accessioning of Trial Boost request to sign off of trial results by Foundation Medicine Pathology for Lung-MAP Trial Boost samples as of May 2023.

FOUNDATION MEDICINE®

© 2023 Foundation Medicine, Inc. | Foundation Medicine®, FoundationReach™, and Trial Boost™ are registered trademarks of Foundation Medicine, Inc.

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | US-FR-2300004